Articles Archives - QualityStocks

FridayApr 17, 2026 12:10 pm

Soligenix Inc. (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status

Designations from established global organizations such as the European Commission carry meaningful implications for biotechnology companies. Soligenix announced that the European Commission granted orphan drug designation to SGX945 for the treatment of Behçet’s disease. SGX945 is based on dusquetide, a synthetic peptide belonging to a class of compounds known as innate defense regulators. Recognition from global regulatory authorities can serve as a powerful validation of a therapy’s potential, particularly in the rare disease space where development challenges are significant and patient needs are urgent. Soligenix (NASDAQ: SNGX) has secured that type of validation, as the European Commission granted orphan drug…

FridayApr 17, 2026 11:30 am

Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Gains Relevance as Inflation, Conflict and Central-Bank Demand Reshape Gold

Disseminated on behalf of  Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising. Central bank gold buying has been unfolding against an international scenario that continues to favor safe-haven assets. Lahontan is working to build value through continued drilling, metallurgical work and project advancement. The company is showing a steady stream of updates this year, including drilling and key financing. Gold’s appeal rarely rests on a single catalyst, and the current environment is no exception. Rising geopolitical tension, stubborn inflation risk, elevated sovereign debt and continued official-sector buying are all feeding the case for a renewed gold cycle,…

FridayApr 17, 2026 10:50 am

Precision Oncology Is Shifting Toward Combination Strategies, Ultimately Changing How New Therapies Are Built

Targeted cancer therapies are increasingly being paired with immunotherapy and chemotherapy to improve outcomes across multiple tumor types First-in-class PP2A inhibitor LB-100 is designed to enhance treatment response by disrupting cancer cell repair mechanisms and boosting immune activity Ongoing clinical trials are exploring LB-100 across solid tumors, including ovarian and colorectal cancers, where unmet need remains high Cancer treatment is entering a phase where the question is no longer which single therapy works best, but how treatments can be combined to improve outcomes. Across oncology, resistance and relapse remain persistent challenges, and the industry’s response has been increasingly clear: multi-drug…

ThursdayApr 16, 2026 11:15 am

ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Nears Drill Program Start as Part of Multi-Pronged Gold Revenue Strategy

Disseminated on behalf of  ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF)and may include paid advertising. Canadian near-term precious metal producer ESGold is advancing toward the May start of a drill program expected to further define priority targets on its 20,618-hectare Montauban Gold-Silver Project in Quebec The company is simultaneously working to construct a fully permitted mill on site and expand the scope of its exploration ESGold is employing a low CapEx strategy that includes funding from a private placement initiative and an agreement with Ocean Partners UK Ltd. that provides a credit facility and a dedicated buyer of gold and silver…

ThursdayApr 16, 2026 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results

Soligenix reports clinical update centered on cutaneous T-cell lymphoma (“CTCL”), a rare form of non-Hodgkin lymphoma that primarily affects the skin. The interim update highlighted that the overall blinded aggregate response rate observed in patients who have completed treatment remains consistent with prior reporting. In addition, the company reported positive results from a study evaluating HyBryte(TM) against Valchlor(R), an existing treatment option for cutaneous T-cell lymphoma. Advancing clinical research while generating positive data is a critical combination in biotechnology, particularly when addressing diseases with limited treatment options. Soligenix (NASDAQ: SNGX) is demonstrating that momentum as it provides both an encouraging…

ThursdayApr 16, 2026 9:45 am

Oncotelic Therapeutics Inc. (OTLC) Expands Beyond Biotech Through AI-Robotics Pivot, Unlocking New Value in GMP Automation

Oncotelic Therapeutics has recently entered a strategic partnership with TechForce Robotics to commercialize a PDAOAI-enhanced, GMP-compliant robotics platform The collaboration integrates AI-driven compliance systems with advanced robotics for pharmaceutical manufacturing automation This pivot underscores a broader strategy: extending Oncotelic’s AI capabilities beyond therapeutics into scalable, high-value industrial applications Oncotelic Therapeutics (OTCQB: OTLC) is signaling a significant strategic evolution, moving beyond its roots as a clinical-stage biotechnology company into the quickly expanding intersection of artificial intelligence and industrial automation. Through two closely aligned announcements, the firm has unveiled a strategic partnership with TechForce Robotics, which positions it to commercialize a next-generation,…

ThursdayApr 16, 2026 9:00 am

American Fusion(TM) Inc. (AMFN) Expands Strategic Positioning at ARPA-E Energy Innovation Summit

American Fusion(TM) used the 2026 ARPA-E Energy Innovation Summit to advance its commercial strategy and expand relationships across the fusion ecosystem. The company is developing innovational decentralized fusion technologies through its wholly owned subsidiary, Kepler Fusion Technologies, centered on the Texatron(TM) platform, targeting data center operators and developers as an initial customer base for future power deployment. American Fusion(TM) is pursuing supply chain relationships for key fusion inputs including helium-3 and deuterium and is also evaluating a potential Frankfurt Stock Exchange listing as part of a broader capital markets strategy. American Fusion(TM) (OTC: AMFN), a developer of next-generation fusion energy…

WednesdayApr 15, 2026 11:15 am

Frontieras North America Inc. Launches New Era for Full Coal Utilization

Frontieras notes milestone moment: groundbreaking of facility based on a new industrial model built on extracting the full value of coal. The company’s proprietary approach reframes coal as a versatile raw material capable of producing a wide spectrum of outputs through controlled processing. At the core of this strategy is Frontieras’s FASForm(TM) process, a solid carbon fractionation technology that separates coal into its constituent components. Recent geopolitical conflict and supply disruptions have underscored how vulnerable global energy systems remain, with oil markets particularly exposed to shocks that can ripple through economies and industries almost instantly. The current situation has renewed…

WednesdayApr 15, 2026 10:30 am

Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF) Is in a Unique Position to Profit From Fossil Fuel and Energy Pressures Dramatically Reshaping Fertilizer Economics

Disseminated on behalf of Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF)and may include paid advertising. The company is advancing its Murdock Mountain phosphate project in Nevada with a focus on direct-application organic fertilizer. Rising oil and natural gas prices are increasing pressure on conventional fertilizer markets, many of which depend on fossil fuel elements and energy-intensive processing. Fertilizer prices have surged in 2026 amid the Middle East conflict and disruptions to shipping through the Strait of Hormuz. Nevada Organic Phosphate’s model centers on raw phosphate requiring simple grinding and bagging rather than energy and fossil fuel intensive chemical processing.…

WednesdayApr 15, 2026 9:45 am

Compact Proton Therapy Delivery Helps Make the Treatment More Accessible for Cancer Patients

For a long time, proton therapy wasn’t available for many cancer patients due to the footprint of traditional proton therapy equipment and the high costs associated with it. However, the size and cost of this equipment is shrinking, opening it up as a more viable treatment option for cancer patients. Liora Technologies, a subsidiary of LIXTE Biotechnology Holdings, Inc., is poised to offer compact, precise, and accessible proton therapy through the innovative Linac for Image Guided Hadron Therapy (“LiGHT”) System. Proton therapy is a specialized cancer treatment that uses precision-guided radiation beams to target and destroy tumors while limiting harm…

Site Search

Company Search

Category: Articles